Financial Performance (Consolidated)

Quarter Ended June 30, 2026 (Q1 FY2027):

  • Revenue from Operations: ₹614.02 Cr (26.0% YoY growth from ₹487.42 Cr in Q1 FY26)
  • Total Income: ₹620.43 Cr (23.9% YoY growth from ₹500.81 Cr)
  • EBITDA: ₹177 Cr (25.2% YoY growth from ₹141 Cr)
  • EBITDA Margin: 28.5% (vs 28.2% in Q1 FY26)
  • Profit After Tax: ₹55.02 Cr (44.6% YoY growth from ₹38.06 Cr)
  • PAT Margin: 8.9% (vs 7.6% in Q1 FY26)
  • Basic EPS: ₹1.43 (vs ₹0.95 in Q1 FY26)
  • Diluted EPS: ₹1.42 (vs ₹0.95 in Q1 FY26)

Operational Highlights:

  • Network expanded to 304 facilities (added 18 new facilities: 1 Tertiary, 15 Secondary, 2 Primary)
  • 16 new surgical facilities commissioned (highest ever in single quarter)
  • 91,082 surgeries performed (15.5% YoY growth)
  • Revenue from India operations: ₹552 Cr (25.3% YoY growth)
  • Revenue from Mature Facilities: ₹485 Cr (37.1% YoY growth)
  • Revenue mix: 77.7% from Services, 22.3% from Products
  • Served over 8.8 lakh patients with 1,050+ doctors

Standalone Performance (Q1 FY2027):

  • Revenue from Operations: ₹382.62 Cr
  • Total Income: ₹386.04 Cr
  • Profit After Tax: ₹16.67 Cr
  • Basic EPS: ₹0.53
  • Diluted EPS: ₹0.52

Board Approvals

1. Statutory Auditors: Appointment of M/s. S.R. Batliboi & Associates LLP (Firm Reg No: 101049W/E300004) as statutory auditors until conclusion of 20th AGM (subject to shareholder approval)

2. Internal Auditors: Appointment of M/s. KPMG Assurance and Consulting Services LLP as internal auditors for FY2026-27, replacing M/s. R.G.N Price & Co.

3. Cost Auditors: Re-appointment of M/s. B Y & Associates (Firm Reg No: 003498) as cost auditors for FY2026-27

4. Nigerian Subsidiary: Approval for Orbit Healthcare Services (Mauritius) Limited (wholly owned subsidiary) to incorporate a wholly owned subsidiary in Nigeria. The new entity will become an indirect wholly owned subsidiary subject to regulatory approvals in Nigeria and Mauritius.

Corporate Actions

  • ESOP Allotment: 175,522 equity shares allotted during Q1 FY2027 (150,282 on April 08, 2026 and 25,240 on May 21, 2026) at exercise prices of ₹84.93, ₹129.88, and ₹135.00 per option
  • Paid-up Capital: Increased to ₹31.70 Cr comprising 31,69,83,028 equity shares
  • IPO Utilization: As of June 30, 2026, ₹282.31 Cr utilized from ₹300 Cr fresh issue proceeds. ₹17.69 Cr remains unutilized (invested in fixed deposits with accrued interest of ₹18 Cr)

Subsidiary Information

Consolidated results include:

  • Dr. Agarwal's Eye Hospital Limited (Subsidiary)
  • Dr. Thind Eye Care Private Limited (Subsidiary)
  • Orbit Healthcare Services (Mauritius) Limited (Subsidiary) with 9 step-down subsidiaries in Africa
  • Elisar Life Sciences Private Limited (Subsidiary)
  • Aditya Jyot Eye Hospital Private Limited (Subsidiary)

African subsidiaries contributed revenues of ₹67.80 Cr and net profit of ₹7.61 Cr for the quarter.

Management Commentary

CEO Dr. Adil Agarwal stated: "This has been an exceptional quarter for us on multiple fronts. We delivered our highest ever sequential quarter-on-quarter revenue growth, underscoring the strong momentum across our business. We also set a new record with the launch of 16 greenfield surgical facilities in a single quarter."

Meeting Details

Board meeting commenced at 11:50 AM IST and concluded at 01:45 PM IST on August 04, 2026.

Auditors' Review

Unaudited financial results reviewed by S.R. Batliboi & Associates LLP with unmodified conclusion. Comparative figures for Q1 FY2026 reviewed by predecessor auditor Deloitte Haskins & Sells.

#Tags: #DrAgarwals #Q1Results #SEBIDisclosure #Healthcare #Growth